iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($)									1 Months Ended		3 Months Ended				5 Months Ended	6 Months Ended	9 Months Ended		12 Months Ended
Basis of Presentation (Details) - USD ($)	May 13, 2020	Apr. 01, 2020	Mar. 31, 2020	Mar. 19, 2020	Oct. 29, 2019	Jul. 12, 2018	Jun. 26, 2018	Jan. 14, 2014	Mar. 31, 2020	Nov. 30, 2018	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Mar. 31, 2019	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2018	Jun. 20, 2018
Basis of Presentation [Line Items]
Accumulated deficit			$ (146,882,000)						$ (146,882,000)		$ (146,882,000)				$ (146,882,000)		$ (146,882,000)		$ (105,821,000)
Net Cash Used in Operating Activities																	(9,478,000)	$ (9,583,000)
Cash			10,040,000						10,040,000		10,040,000			$ 9,037,000	10,040,000		10,040,000	9,037,000	4,421,000		$ 15,934,000
Proceeds from exercise of warrants															6,400,000		6,330,000	0
Net proceeds from underwritten public offering					$ 4,500,000
Stock Issued During Period, Value, New Issues							$ 16,000,000							0
Shares of the common stock issued							4,350,000
Gross proceeds from issuance					$ 4,520,000
Contract liabilities			$ 3,006,000						$ 3,006,000		3,006,000				$ 3,006,000		3,006,000		1,279,000
Contract with Customer, Liability, Revenue Recognized											$ 75,000						193,000
Proceeds from capital contribution										$ 2,500,000							$ 0	$ 2,459,000
Term of agreement								5 years
Stock Issued During Period, Shares, Warrants Exercised															29,100,000	14,999,998
Lincoln Park 2020 Purchase Agreement
Basis of Presentation [Line Items]
Shares of the common stock issued			5,000,000	815,827					5,000,000								15,000,000
Number of shares offered				1,000,000
Gross proceeds from issuance			$ 5,766,000						$ 5,800,000								$ 15,700,000
Authorized value of shares				$ 50,000,000
Term of agreement				36 months
CC-Pharming Ltd
Basis of Presentation [Line Items]
Contract with Customer, Liability																				$ 2,900,000
Contract with Customer, Liability, Revenue Recognized																	147,000		$ 1,800,000
Master Manufacturing Services and Supply Agreement ("MSA") \| Lung Bio
Basis of Presentation [Line Items]
Advance received													$ 1,600,000
Purchase of capital expenditure													1,000,000
Related contracted services													$ 620,000
Contract liabilities												$ 1,600,000				$ 1,600,000
Contract with Customer, Liability, Revenue Recognized																	$ 46,000
Over-Allotment Option [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues						$ 1,350,000
Shares of the common stock issued						1,500,000
Shares Issued, Price Per Share						$ 0.90
Number of shares offered							2,666,666
Gross proceeds from issuance						$ 1,350,000
Common Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues														$ 0
Shares of the common stock issued					2,450,000		4,350,000							142,000
Shares Issued, Price Per Share							$ 0.90															$ 0.90
Stock Issued During Period, Shares, Warrants Exercised											31,860,000	3,140,000
Series A Warrants [Member]
Basis of Presentation [Line Items]
Shares of the common stock issued					25,000,000
Stock Issued During Period, Shares, Warrants Exercised																3,300,000
Series A Preferred Stock [Member]
Basis of Presentation [Line Items]
Shares of the common stock issued							6,300
Series B Preferred Stock [Member]
Basis of Presentation [Line Items]
Shares of the common stock issued							5,785
Shares Issued, Price Per Share					$ 0.20																	$ 0.90
Subsequent event \| Lincoln Park 2020 Purchase Agreement
Basis of Presentation [Line Items]
Shares of the common stock issued		10,000,000
Gross proceeds from issuance		$ 9,962,600
Subsequent event \| Securities and Exchange Commission \| Lincoln Park 2020 Purchase Agreement
Basis of Presentation [Line Items]
Stock Issued During Period, Value, New Issues	$ 1,090,000
Shares of the common stock issued	1,000,000
Shares Issued, Price Per Share	$ 1.09